Galderma’s Mirvaso Joins Rosacea Market With Indication For Facial Erythema
This article was originally published in The Pink Sheet Daily
The dermatology company is able to offer a continuum of care for patients with the skin condition now that it has received FDA approval for a third product to treat the condition. The latest offering treats the most mild form of the condition.
You may also be interested in...
Vicept Acquired By Allergan For $75M Upfront
Allergan adds to its dermatology portfolio with the acquisition of closely-held Vicept.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.